Abliva AB (Nasdaq Stockholm: ABLI) today announces that the number of shares and votes in the Company has increased by 262,500,000, as a result of the conversion of a convertible loan announced by the Board of Directors on 22 February 2024.
Today, the last trading day of the month, there are a total of 1,611,884,536 shares and votes in Abliva AB.
This information is information that Abliva AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-08-30 08:30 CEST.
Abliva – Delivering mitochondrial health
Abliva discovers and develops medicines for the treatment of mitochondrial disease. This rare and often very severe disease occurs when the cell’s energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, has entered late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI). For more information, please visit www.abliva.com. Subscribe to our news and follow us on LinkedIn and YouTube.
For more information, please contact:
Catharina Johansson, Deputy CEO, CFO & VP Investor Relations
+46 (0)46-275 62 21, ir@abliva.com
Abliva AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@abliva.com, www.abliva.com